Engineered compositions for bone-targeted therapy
AssigneeWilliam Marsh Rice University
InventorsHan XIAO, Chenfei YU, Zeru TIAN
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for treating bone disease, such as bone cancers or bone metastasis of cancers, by administering an engineered bone-targeting compositions, such as an antibody or one or more polypeptides, such as an antibody or polypeptide engineered to comprise bone-homing peptide(s). Further provided herein are bone-targeting compositions, such as an antibody or one or more polypeptides, such as an antibody or polypeptide engineered to comprise bone-homing peptide(s).
Claims79
A bone-targeting antibody engineered to comprise at least one bone-homing peptide which selectively binds to bone hydroxyapatite (HA).
The method of any of claims 25-34, wherein the bone-targeting antibody results in increased concentration of therapeutic antibody at the bone tumor niche, inhibits cancer development in the bone, and/or limits secondary metastases to other organs.
The method of claim 41 or 43, wherein the bone-homing peptide is L-Asp6.
A bone-targeting composition comprising one or more polypeptides engineered to comprise at least one bone-homing peptide which selectively binds to bone hydroxyapatite (HA).
The method of any of claims 59-68, wherein the bone-targeting composition results in increased concentration of therapeutic polypeptide at the bone tumor niche, inhibits cancer development in the bone, and/or limits secondary metastases to other organs.
The method of claim 75 or 77, wherein the bone-homing peptide is L-Asp6.
1 The method of any of claims 25-31, wherein the bone disease is wherein the bone disease is osteoporosis, osteomalacia, periodontitis, rheumatoid arthritis, metabolic bone disease, a parathyroid disorder, steroid-induced osteoporosis, chemotherapy-induced bone loss, pre-menopausal bone loss, fragility and recurrent fractures, renal osteodystrophy, bone infections, or Paget's disease.
1 The method of claim 60, wherein the bone disease is osteoporosis, osteomalacia, periodontitis, rheumatoid arthritis, metabolic bone disease, a parathyroid disorder, steroid-induced osteoporosis, chemotherapy-induced bone loss, pre-menopausal bone loss, fragility and recurrent fractures, renal osteodystrophy, bone infections, or Paget's disease.
Dependencies are inferred from the claim text.